UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 128

Sortiert nach

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

Annals of oncology, 1998-09, Vol.9 (9), p.995-1001

1998

Link zum Volltext

Verfügbarkeit prüfen

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program

Journal of clinical oncology, 1998-08, Vol.16 (8), p.2825-2833

1998

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

Journal of clinical oncology, 1999-01, Vol.17 (1), p.268-276

1999

Link zum Volltext

Verfügbarkeit prüfen

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

Annals of oncology, 1999-06, Vol.10 (6), p.655-661

1999

Link zum Volltext

Verfügbarkeit prüfen

Rituximab in indolent lymphoma : The single-agent pivotal trial

Seminars in oncology, 1999-10, Vol.26 (5), p.79-87

1999

Link zum Volltext

Verfügbarkeit prüfen

Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity

Journal of clinical oncology, 2001-04, Vol.19 (8), p.2153-2164

2001

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B-Cell Non-Hodgkin's Lymphoma

Journal of clinical oncology, 1999-12, Vol.17 (12), p.3793-3803

1999

Link zum Volltext

Verfügbarkeit prüfen

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

Journal of clinical oncology, 2000-09, Vol.18 (17), p.3135-3143

2000

Link zum Volltext

Verfügbarkeit prüfen

Complement activation plays a key role in the side‐effects of rituximab treatment

British journal of haematology, 2001-12, Vol.115 (4), p.807-811

2001

Link zum Volltext

Verfügbarkeit prüfen

Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity

Annals of oncology, 1999-12, Vol.10 (12), p.1525-1527

1999

Link zum Volltext

Verfügbarkeit prüfen

A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia

Seminars in oncology, 2000-12, Vol.27 (6), p.99-103

2000

Link zum Volltext

Verfügbarkeit prüfen

Response criteria for NHL: Importance of ‘normal’ lymph node size and correlations with response rates

Annals of oncology, 2000-04, Vol.11 (4), p.399-408

2000

Link zum Volltext

Verfügbarkeit prüfen

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy

Annals of oncology, 2001-01, Vol.12 (1), p.109-114

2001

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab

Leukemia & lymphoma, 2006-09, Vol.47 (9), p.1830-1840

2006

Link zum Volltext

Verfügbarkeit prüfen

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma

Current pharmaceutical biotechnology, 2000-07, Vol.1 (1), p.1

2000

Link zum Volltext

Verfügbarkeit prüfen

Rituximab : An insider's historical perspective

Seminars in oncology, 2000-12, Vol.27 (6), p.9-16

GRILLO-LOPEZ, Antonio J

2000

Link zum Volltext

Verfügbarkeit prüfen

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy

Leukemia, 2003-08, Vol.17 (8), p.1658-1664

2003

Link zum Volltext

Verfügbarkeit prüfen

Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils

Leukemia, 2002-04, Vol.16 (4), p.693-699

2002

Link zum Volltext

Verfügbarkeit prüfen

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

Journal of clinical oncology, 1997-10, Vol.15 (10), p.3266-3274

1997

Link zum Volltext

Verfügbarkeit prüfen

Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a

Clinical cancer research, 2000-07, Vol.6 (7), p.2644

2000

Link zum Volltext

Verfügbarkeit prüfen

ANTIBODY-TARGETED IMMUNOTHERAPY FOR TREATMENT OF MALIGNANCY

Annual review of medicine, 2001-01, Vol.52 (1), p.125-145

2001

Link zum Volltext

Verfügbarkeit prüfen

IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

Blood, 1997-09, Vol.90 (6), p.2188-2195

1997

Link zum Volltext

Verfügbarkeit prüfen

Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma

Current pharmaceutical biotechnology, 2001-12, Vol.2 (4), p.301

2001

Link zum Volltext

Verfügbarkeit prüfen

Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999

Clinical cancer research, 2000-01, Vol.6 (1), p.317-318

2000

Link zum Volltext

Verfügbarkeit prüfen

Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up

Journal of clinical oncology, 2004-12, Vol.22 (23), p.4711-4664

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 128

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(90)

Publikationsform

Artikel
(127)
Buchkapitel
(1)

Sprache

Englisch
(122)
Japanisch
(15)
Spanisch
(6)

Erscheinungsjahr

n.n

Thema

Humans
(90)
Life Sciences & Biomedicine
(71)
Science & Technology
(71)
Oncology
(61)
Biological And Medical Sciences
(50)
Medical Sciences
(50)
Male
(48)
Female
(43)
Rituximab
(42)
Antineoplastic Agents
(41)
Middle Aged
(41)
Pharmacology. Drug Treatments
(41)
Antibodies, Monoclonal - Therapeutic Use
(37)
Antibodies, Monoclonal, Murine-Derived
(37)
Antineoplastic Agents - Therapeutic Use
(36)
Adult
(35)
Aged
(34)
Immunotherapy
(24)
Antibodies, Monoclonal - Administration & Dosage
(19)
United States
(16)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program

Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

Rituximab in indolent lymphoma : The single-agent pivotal trial

Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity

Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B-Cell Non-Hodgkin's Lymphoma

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

Complement activation plays a key role in the side‐effects of rituximab treatment

Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity

A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia

Response criteria for NHL: Importance of ‘normal’ lymph node size and correlations with response rates

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy

Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma

Rituximab : An insider's historical perspective

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy

Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a

ANTIBODY-TARGETED IMMUNOTHERAPY FOR TREATMENT OF MALIGNANCY

IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma

Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999

Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up

Suchergebnisse filtern